Relapsed or Refractory Multiple Myeloma

Oncology·MeSH: Multiple Myeloma

Prevalence

17.0 / 100K

Incidence

7.0 / 100K/yr

22 drugs in development·11 companies·7 clinical trials

Drug Pipeline by Phase

Phase 3(8)

Phase 2(2)

Drug	Company
EOS-448	iTeos Therapeutics, Inc. (ITOS)
incb001158	Incyte Corp. (INCY)

Phase 1(5)

Drug	Company
ACLX-001	Arcellx, Inc. (ACLX)
Carfilzomib	Merus N.V. (MRUS)
CB-011	Caribou Biosciences, Inc. (CRBU)
jnj-79635322	GH Research PLC (GHRS)
jnj-87562761	GH Research PLC (GHRS)

Phase 1/Phase 2(5)

Phase 4(2)

Drug	Company
BMS-986393	BRISTOL MYERS SQUIBB CO (BMY)
mRNA-2808	Moderna, Inc. (MRNA)

BioSniper tracks 22 drugs in development for Relapsed or Refractory Multiple Myeloma across 11 companies.

There are 7 clinical trials targeting Relapsed or Refractory Multiple Myeloma tracked by BioSniper.

The estimated prevalence of Relapsed or Refractory Multiple Myeloma is approximately 17.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.